Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting

García-Malo, Celia; Miranda, Carolina; Ponte, Sabela Novo; Peralta, Sofía Romero; Cano-Pumarega, Irene; Boi, Sara; Vidal, Verónica; Anguizola, Samantha; Botta, Laura; Garcı́a-Borreguero, Diego

doi:10.1016/j.sleep.2020.06.002

Cited by 6 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can result from altered iron acquisition by the brain (Connor et al, 2011), and is reflected by reduced cerebrospinal fluid (CSF) ferritin in the context of normal serum levels in people with RLS (Earley et al, 2000). In line with this, transcranial ultrasound of the substantia nigra showed hypoechogenicity in people with RLS (Garcia-Malo, Miranda, et al, 2020a;Garcia-Malo, Wanner, et al, 2020b;Godau, Schweitzer, Liepelt, Gerloff, & Berg, 2007;Godau et al, 2008;Schmidauer et al, 2005).…”

Section: Brain Iron Deficiencymentioning

confidence: 78%

Restless legs syndrome: Over 50 years of European contribution

Khachatryan

Ferri

Fulda

et al. 2022

Journal of Sleep Research

View full text Add to dashboard Cite

Summary Restless legs syndrome (RLS) is a sensorimotor neurological disorder characterised by an urge to move the limbs with a circadian pattern (occurring in the evening/at night), more prominent at rest, and relieved with movements. RLS is one of the most prevalent sleep disorders, occurring in 5%–10% of the European population. Thomas Willis first described RLS clinical cases already in the 17th century, and Karl‐Axel Ekbom described the disease as a modern clinical entity in the 20th century. Despite variable severity, RLS can markedly affect sleep (partly through the presence of periodic leg movements) and quality of life, with a relevant socio‐economic impact. Thus, its recognition and treatment are essential. However, screening methods present limitations and should be improved. Moreover, available RLS treatment options albeit providing sustained relief to many patients are limited in number. Additionally, the development of augmentation with dopamine agonists represents a major treatment problem. A better understanding of RLS pathomechanisms can bring to light novel treatment possibilities. With emerging new avenues of research in pharmacology, imaging, genetics, and animal models of RLS, this is an interesting and constantly growing field of research. This review will update the reader on the current state of RLS clinical practice and research, with a special focus on the contribution of European researchers.

show abstract

Section: Brain Iron Deficiencymentioning

confidence: 78%

Restless legs syndrome: Over 50 years of European contribution

Khachatryan

Ferri

Fulda

et al. 2022

Journal of Sleep Research

View full text Add to dashboard Cite

show abstract

“…Intravenous iron supplementation may be considered if oral iron is not tolerated or effectively absorbed, and in patients with severe RLS symptoms, there are currently several formulations with the best evidence supporting the use of carboxymethyl iron, with a total dose of 1000-1500 mg in single or fractional infusions. [ 55 ]…”

Section: Therapeuticsmentioning

confidence: 99%

Exploration of restless legs syndrome under the new concept: A review

2022

View full text Add to dashboard Cite

Restless leg syndrome (Restless legs syndrome, RLS) is a common neurological disorder. The pathogenesis of RLS remains unknown, and recent pathophysiological developments have shown the contribution of various genetic markers, neurotransmitter dysfunction, and iron deficiency to the disease, as well as other unidentified contributing mechanisms, particularly chronic renal dysfunction. RLS enhancement syndrome is frequently observed in patients with RLS who have received long-term dopamine agonist therapy, manifesting as a worsening of RLS symptoms, usually associated with an increase in the dose of dopamine agonist. Some patients with RLS can adequately control their symptoms with non-pharmacological measures such as massage and warm baths. First-line treatment options include iron supplementation for those with evidence of reduced iron stores, or gabapentin or pregabalin, as well as dopamine agonists, such as pramipexole. Second-line therapies include opioids such as tramadol. RLS seriously affects the quality of life of patients, and because its pathogenesis is unclear, more biological evidence and treatment methods need to be explored.Abbreviations: BID = brain iron deficiency, CNS = central nervous system, GABA = gamma-aminobutyric acid, IRLSSG = International restless leg syndrome research group, PLMD = periodic limb movement disorder, PLMS = periodic leg movement in sleep, RLS = restless legs syndrome, WED = Willis-Ekbom disease.

show abstract

The relationship between sleep disorders, anxiety, depression, and cognitive function with restless legs syndrome (RLS) in the elderly

Wen

et al. 2021

Sleep Breath

View full text Add to dashboard Cite

Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting

Cited by 6 publications

References 33 publications

Restless legs syndrome: Over 50 years of European contribution

Restless legs syndrome: Over 50 years of European contribution

Exploration of restless legs syndrome under the new concept: A review

The relationship between sleep disorders, anxiety, depression, and cognitive function with restless legs syndrome (RLS) in the elderly

Contact Info

Product

Resources

About